XJPX7747
Market cap4.40bUSD
Dec 24, Last price
2,545.00JPY
1D
-0.35%
1Q
-0.86%
Jan 2017
114.99%
Name
Asahi Intecc Co Ltd
Chart & Performance
Profile
Asahi Intecc Co., Ltd. engages in the development, manufacture, and sale of medical devices in Japan, the United States, Europe, China, and internationally. It operates through two segments: the Medical Division and the Device Division. The company provides percutaneous transluminal coronary angioplasty (PTCA) guide wires, PTCA guiding catheters, PTCA balloon catheters, and penetration catheters for cardiology; peripheral guide wires, IVR guide wires, micro catheters, and gastrointestinal and cerebrovascular system guide wires for peripheral vascular, abdominal vascular, and cerebrovascular systems; and guide wires and catheters for angiography. It also offers OEM/ODM services for medical devices; and medical and industrial components, such as element wires, stranded conductors, coils, tubes, terminal processing products, and other products, as well as develops, manufactures, and sells ultra-fine stainless steel wire ropes, terminal processed products, etc. The company was formerly known as Asahi Mini Rope Sales Co., Ltd. and changed its name to Asahi Intecc Co., Ltd. in July 1988. Asahi Intecc Co., Ltd. was incorporated in 1976 and is headquartered in Aichi, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 107,547,000 19.36% | 90,101,000 15.89% | 77,748,000 26.41% | |||||||
Cost of revenue | 82,468,000 | 47,045,000 | 41,321,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 25,079,000 | 43,056,000 | 36,427,000 | |||||||
NOPBT Margin | 23.32% | 47.79% | 46.85% | |||||||
Operating Taxes | 5,893,000 | 4,467,000 | 4,737,000 | |||||||
Tax Rate | 23.50% | 10.37% | 13.00% | |||||||
NOPAT | 19,186,000 | 38,589,000 | 31,690,000 | |||||||
Net income | 15,808,000 20.62% | 13,106,000 20.71% | 10,857,000 8.74% | |||||||
Dividends | (3,933,000) | (3,256,000) | (2,994,000) | |||||||
Dividend yield | 0.64% | 0.43% | 0.54% | |||||||
Proceeds from repurchase of equity | (1,355,000) | 15,970,000 | ||||||||
BB yield | 0.22% | -2.87% | ||||||||
Debt | ||||||||||
Debt current | 5,615,000 | 10,361,000 | 5,815,000 | |||||||
Long-term debt | 1,087,000 | 5,507,000 | 7,404,000 | |||||||
Deferred revenue | 2,530,000 | 2,053,000 | ||||||||
Other long-term liabilities | 4,430,000 | 1,687,000 | 1,119,000 | |||||||
Net debt | (47,361,000) | (30,416,000) | (29,089,000) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 34,708,000 | 19,138,000 | 17,302,000 | |||||||
CAPEX | (9,877,000) | (12,713,000) | (8,560,000) | |||||||
Cash from investing activities | (21,222,000) | (15,135,000) | (18,703,000) | |||||||
Cash from financing activities | (13,878,000) | (2,342,000) | 11,368,000 | |||||||
FCF | 15,320,000 | 25,387,000 | 24,272,000 | |||||||
Balance | ||||||||||
Cash | 38,658,000 | 36,884,000 | 32,321,000 | |||||||
Long term investments | 15,405,000 | 9,400,000 | 9,987,000 | |||||||
Excess cash | 48,685,650 | 41,778,950 | 38,420,600 | |||||||
Stockholders' equity | 130,186,000 | 232,025,000 | 209,005,000 | |||||||
Invested Capital | 114,406,350 | 108,680,050 | 95,130,400 | |||||||
ROIC | 17.20% | 37.87% | 36.83% | |||||||
ROCE | 14.95% | 27.89% | 26.54% | |||||||
EV | ||||||||||
Common stock shares outstanding | 271,625 | 271,625 | 271,480 | |||||||
Price | 2,255.50 -19.76% | 2,811.00 37.26% | 2,048.00 -22.89% | |||||||
Market cap | 612,650,188 -19.76% | 763,537,875 37.33% | 555,991,040 -20.18% | |||||||
EV | 566,033,188 | 854,555,875 | 638,170,040 | |||||||
EBITDA | 34,798,000 | 51,767,000 | 43,900,000 | |||||||
EV/EBITDA | 16.27 | 16.51 | 14.54 | |||||||
Interest | 226,000 | 308,000 | 141,000 | |||||||
Interest/NOPBT | 0.90% | 0.72% | 0.39% |